No Data
No Data
Mesoblast's Ryoncil Awaits FDA Approval for SR-aGVHD
FDA has accepted Mesoblast's (mesoblast) application for the market authorization of its off-the-shelf cell therapy.
FDA accepts the application for the listing of Mesoblast's (mesoblast) spot-specific cell therapy.
Express News | Mesoblast Ltd : Piper Sandler Raises to Overweight From Neutral; Raises Target Price to $11 From $4
FDA Accepts Mesoblast's Latest BLA for Paediatric GvHD Cell Therapy
Mesoblast Raised to Overweight From Neutral by Piper Sandler
Mesoblast Price Target Raised to $11.00/Share From $4.00 by Piper Sandler
No Data
101674396 : Hold or sell?
Trytosaveabit OP 101674396 : Sorry I don’t give buy/sell advice! There’s no way for me to know others risk tolerance or the type of trade they are doing! I will say that I am still bullish on this! NFA JMO! GL